Health concept stocks include China Pacific Insurance, Wuxi PharmaTech, Aier Ophthalmology, zhifei Bio, BOE A, Guotai Junan, Yunnan Baiyao, Fosun Pharma, Tiger Pharmaceuticals, Kanglong Chenghua and other 109 listed companies. What other health-related stocks are brought by the following small series? Let's take a look, hoping to bring some reference.

What other health-related stocks are there?

1, Anel (002875): The company is mainly engaged in high-end children's wear business. 65438+February 2 1, Anna Nair opened at 23.2 yuan and closed at 25.380 yuan, up 10.0 1%. The highest price on that day was 25.38 yuan, and the lowest price was 225 1 yuan, with a turnover of 28.224 million lots and a total market value of 5.397 billion yuan.

2. Guolian Aquatic Products (300094): The company's main business is shrimp and tilapia fry, aquatic feed, primary processed products and deep processed food. Southern Fortune Network 65438+February 2 1 news, the stock price of Guolian Aquatic Products rose by 6.07% to close at 6.470 yuan, with a market value of 7.334 billion yuan. The highest intraday share price was 6.68 yuan, and the lowest was 6. 1 yuan, with 654.38+45 million lots sold.

3. Haizheng Pharmaceutical (600267): The company is mainly engaged in the research and development, production and sales of raw materials and preparations. Southern Fortune Network 65438+February 2 1, Haizheng Pharmaceutical's share price rose 4%, closing at 1 1. 190 yuan, with a market value of134.08 million yuan. The highest intraday share price was 1 1.69 yuan, and the lowest was 10.82 yuan, with a turnover of 2823 1.50 million lots.

4. Shu Hua Sports (605299): The company is mainly engaged in research and development, production and sales of fitness equipment and display shelf products. On the evening of February 2, 65438+1,the latest news of Shu Hua sports1170 yuan increased by 2.95%. 9 15 19000 lots with a total market value of 4.596 billion yuan.

5. Jiuan Medical (002432): The company's business includes research and development, production and sales of household medical devices. Beijing time 65438+February 2 1, Jiu 'an Medical opened at 59.24 yuan and closed at 60.820 yuan, up 2.65% from the previous trading day to 59.25 yuan. The highest price on that day was 6 1.56 yuan, and the lowest price was 58.88 yuan. The turnover was 28177,000 lots with a total market value of 29.45 billion yuan.

6. Wang Xi Food (000639): The company's main business is Xiwangpai series healthy edible oil. 65438+February 2 1 Wang Xi Food resumed trading in the evening, and its share price fell by 0.4 1% within 7 days. This year, the growth rate dropped by -6 12%, and the latest price was 4.900 yuan, up by 2.3%, with a market value of 5.289 billion yuan.

7. Light Media (30025 1): The company is engaged in film business. 65438+February 2 1 resumption of trading in the evening news, the share price of Light Media fell by 4.36% in five days, and this year's increase fell by -5.66 1%, with the latest report of 8.250 yuan, and the transaction was10.2 billion yuan.

8. Kexing Pharmaceutical (688 136): The company is engaged in research and development, production and sales of biopharmaceuticals. 65438+February 2 1 news, Kexing Pharmaceutical opened at 24.2 1 yuan and closed at 24.800 yuan, up 2.44%. The highest price on that day was 25.36 yuan, and the lowest was 2.4 1 yuan, with a total market value of 4.928 billion yuan.

What are the leading health concept stocks?

1, Dean Diagnostics (28.30+ 1.25%, consulting unit): The high-end accurate diagnosis technology platform has been laid out, and the cooperative construction business has grown rapidly, and it has expanded to a number of 3A hospital customers to build an accurate platform.

2. Kangmei Bio (23.45+0.04%, clinical unit): obtained the product registration certificate of 145 in vitro diagnostic reagent, covering biochemistry, blood cells and other fields.

3. Jiuzhoutong (20.04+0.50%): Haoyaoshi Pharmacy, a wholly-owned subsidiary of Jiuzhoutong, signed a strategic cooperation framework agreement with Kang Sheng Medicine, and plans to gradually realize the cooperation between Kangyuan medicine series and big health food series within three years.

4. Lejin Health (6.26-1.1%,consulting unit): The company is one of the earliest enterprises engaged in the research and development of home sauna equipment in China, and is a pioneer in promoting healthy sauna to ordinary families in China. The main products mainly include domestic far-infrared sauna rooms and portable sauna products.

5. Peking University Medicine (000788): Acquired Beijing Medical Medicine to complete business expansion. 20 1 1, the company acquired 0/00% equity of Buyi Medicine from Peking University International Hospital Group. From 20 1 1, Beijing Pharmaceutical and its subsidiaries are included in the company's statements. The company added the sales and circulation business of drugs and medical devices, and the pharmaceutical industry chain was further extended.

What are the leading stocks in medical American stocks?

1. kaineng health: the net profit of the interim report increased by 80.73% in advance, and increased by 47.83% in the first half of 2002/kloc-0; Jiyuan Ye Mei, a wholly-owned subsidiary of the company, is committed to innovation and development of cell-level skin repair technology. The core products adopt the world-leading clinical biological protein gene recombination and self-patented protein recombination technology, which has effective anti-aging repair and beauty fields. The main reason for the change in the company's performance is that the downstream market of products has been opened, no longer affected by the epidemic, and the industry prosperity index has gradually recovered. In 20021year, the company seized all the business opportunities of global consumption recovery, launched various new products, improved the industrial chain and achieved substantial growth in performance.

2. Aoyuan Meigu: net profit forecast of interim report 127.46%, 202 1 increase in the first half of the year178.03%; Guangzhou Ogilvy & Mather, a wholly-owned subsidiary of the company, set up a joint venture with KD Company * * *, and the joint venture company represented products in China. KD was founded in Korea. As can be seen from its main business, it is a high-tech company that sells medical beauty equipment and develops active raw materials for beauty. The reason for the surge in performance is also the factor brought about by the merger. In the second quarter, Zhejiang Liantianmei Company was acquired. In the first half of last year, due to the epidemic situation, the production and sales of chemical fiber plates were affected to some extent.

3. Ha Sanlian: The net profit forecast of the interim report is 1892. 1 1%, and the growth rate of 202 1 in the first half of the year is 251.58%; The reason why Harbin Sanlian fits medical beauty is because it has invested in women and children's homes. Its main products are mostly medical beauty products, including: medical sodium hyaluronate repair patch, medical sodium hyaluronate repair solution and so on. The company's foreign investment holds 65,438+000% equity of Beixing Pharmaceutical, and the reason for the increase in the semi-annual report is mainly affected by non-recurring gains and losses. The company confirmed that the impact of investment income on the profit and loss of the company's consolidated statements in 20021year was about RMB 566 million.

4. The annual net profit of Huaxi Bio is predicted to be 35.00%, with an increase of 65,438+002.23% in the first half of 2002/kloc-0; As an authentic leader in the medical and beauty industry, the company is currently a core high-tech enterprise, the world's leading producer of hyaluronic acid microbial fermentation, and its industrial scale ranks among the top in the world. At the same time, it is also one of the earliest enterprises to produce hyaluronic acid by microbial fermentation. In June last year, the company also acquired 0/00% equity of Forsyte/KLOC, and built the production equipment of hyaluronic acid series products ahead of domestic time. The reason for the pre-increase of the company's semi-annual report is mainly due to the growth of raw material business and medical terminal business. Its skin care business has been singing all the way in the first half of the year, bringing the company nearly 100% revenue growth. At the same time, during the period of revenue growth, the company also increased its efforts to give strong support to the underlying technology research and development.

5. Langzi shares: the net profit forecast of the interim report is 3228.26%, 202 1 pre-increase in the first half of the year105.52%; The three major domestic medical beauty brands "Milan", "Crystal Skin" and "Gao Yisheng" are all controlled by Langzi, and they have also invested in DMG, a well-known Korean medical beauty group, in the international market. This year, in addition to speeding up the pace in the women's wear industry chain, we have also made continuous progress in medical beauty, achieving steady business development, which is of great help to the company's profits.

6. Haohaishengke: the net profit forecast of the interim report is 753.70%, 202 1 pre-increase in the first half of the year192.55%; The company specializes in R&D, production and sales of the whole industrial chain from upstream raw materials to terminal preparations, and produces raw materials in two ways to adapt to the current trend. The change of company performance mainly comes from the epidemic situation. In the first half of this year, the epidemic situation was effectively controlled, so as to carry out various market activities, expand the influence and increase the demand for products.

7. Special drug shares: the net profit forecast of the interim report is 180.00%, 202 1 21.00% in the first half of the year; The company plans to invest 6,543.8 billion yuan to set up Guangdong Temei Health Science and Technology Industry Co., Ltd., and plans to set up the company as an investment and operation platform for the big health industry of the special pharmaceutical industry group. The development direction includes the development and investment of medical beauty services. The sales volume of the company's core products has gradually increased, and the business has also returned to normal level. The company has continuously strengthened brand building, optimized product structure, increased internal management, persisted in reducing costs and increasing efficiency, and achieved good results.

8. Blonde Rabbi: The net profit of the interim report is predicted to be 1 14.72%, and the growth rate in the first half of 2002139 438+0%; The company has old experience in the medical beauty industry, invested in Guangdong Hanfei Hospital, a medical beauty enterprise, and also holds five medical beauty institutions under the company. The company's business plan is carried out in an orderly manner, and the online and offline channel layout, marketing strategy, management mode and product research and development mode are adjusted. Compared with the same period last year, the company's income has recovered to a great extent this year.

9. Chengzhi shares: the net profit forecast of the interim report is 458.77%, and the pre-increase in the first half of 2002/kloc-0 is 24.54%; Official website shows that Chengzhi Life Science and Technology Co., Ltd., a wholly-owned subsidiary, produces hyaluronic acid. The supply and demand of domestic medical beauty have improved significantly after the epidemic last year. Due to the reversal of raw material prices in the clean energy business, the sales of related products of the company increased significantly. At the same time, the company's market demand for semiconductor liquid crystal display materials has increased, and the production and sales volume have increased substantially, which has also brought about an increase in the company's profits.

10. Huilong shares: the net profit forecast of the interim report 100.00%, and the increase in the first half of 2002135.71%; Haihua technology has long been concerned about the production technology of hyaluronic acid products, and has produced related products on a pilot scale. Shanghai Hua Shao Biotechnology Development Co., Ltd., a subsidiary of Haihua Technology, is mainly responsible for the promotion, sales and technology research and development of the company's future medical and beauty products. The company's chemical trade business adjusted its business ideas, focused on core suppliers, core customers and core products, and strengthened management and control, and its business performance increased substantially year-on-year.

What leading stocks are there in the health industry?

Leading stock 1, Lexin Medical: The company's business includes the research and development and operation of intelligent health cloud platform.

Leading stock 2. Rongjie Health: The company is engaged in the research, development, production and sales of far-infrared health equipment.

Leading stock 3. Xinyue Health: The company is mainly engaged in big health industry, building ceramics business and ecological health building materials business.

Recent situation of healthy leading stocks

Lexin Medical: Leading Shares

In the past five days, the share price of Lexin Medical fell by 4.04%, and the total market value fell by 83.7335 million. The current market value is 2.074 billion yuan. In 2022, the stock price fell by -72.05%. 65438+February 2 1 news, Lexin Medical 65438+February 2 1 net outflow of main funds 1463600 yuan, net outflow of bulk funds 1463600 yuan, net outflow of retail funds13485000 yuan.

Rongjie Health: Leading Stock

In the past five trading days, the stock price fell by 7.77%, with the highest price of 4. 1 1 yuan, and the total market value fell by 233 million. 65438+February 2 1 news, Rongjie Health has a net inflow of RMB 45010.03 million, a net inflow of oversized bills of RMB 1. 1.9 million, and a net outflow of retail investors of RMB1.831.

Xinyue Health: Leading Shares

In the past five trading days, the stock price rose by 7.74%, with the highest price of 5.39 yuan, the total market value rose by 36. 1 billion, and the current market value was 4.67 billion yuan. In terms of capital flow data, on June 5438+February 2 1 day, the net outflow of main funds was 9,50910.5 million yuan, the net outflow of super-large single funds was 78,050,200 yuan, the net outflow of large single funds was10.704/kloc-0.3 million yuan, and the net inflow of retail funds was 3,000 yuan.

Lexin Medical Treatment (300562)

The financial report shows that in the third quarter of 2022, the company's operating income was 299 million yuan; The net profit attributable to listed shareholders is 2,054,900 yuan; The income from fully diluted net assets is 0.19%; Gross profit margin is 23.24%, and earnings per share is 0.0 1 yuan.

Rongjie Healthy (300247)

Rongjie Health released its financial report for the third quarter of 2022, achieving an operating income of 94.5235 million yuan, a year-on-year increase of -4.88%, and a net profit of 37 1.3 1 10,000 yuan, a year-on-year increase of -82.7%.

Xinyue Health (002 162)

The financial report shows that in the third quarter of 2022, the company's operating income was 350 million yuan; The net profit attributable to listed shareholders is-76,954,500 yuan; Fully diluted net assets income-6.22%; Gross profit margin is 20.6% and earnings per share is -0.08 yuan.